0000899243-20-019846.txt : 20200721 0000899243-20-019846.hdr.sgml : 20200721 20200721191924 ACCESSION NUMBER: 0000899243-20-019846 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200720 FILED AS OF DATE: 20200721 DATE AS OF CHANGE: 20200721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Murcko Mark CENTRAL INDEX KEY: 0001816130 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39385 FILM NUMBER: 201039908 MAIL ADDRESS: STREET 1: C/O RELAY THERAPEUTICS, INC. STREET 2: 399 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Relay Therapeutics, Inc. CENTRAL INDEX KEY: 0001812364 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-370-8837 MAIL ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-20 0 0001812364 Relay Therapeutics, Inc. RLAY 0001816130 Murcko Mark C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2020-07-20 4 C 0 281617 A 718123 D Common Stock 2020-07-20 4 C 0 278829 A 996952 D Common Stock 2020-07-20 4 P 0 25000 20.00 A 1021952 D Series A Convertible Preferred Stock 2020-07-20 4 C 0 1000000 0.00 D Common Stock 281617 0 D Series B Convertible Preferred Stock 2020-07-20 4 C 0 990099 0.00 D Common Stock 278829 0 D Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. On July 20, 2020, the reporting person purchased 25,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering. /s/ Brian R. Adams, as Attorney-in-Fact 2020-07-21